8
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Incentivos y desincentivos de la industria farmacéutica privada para la I+D de nuevos medicamentos Translated title: Incentives and disincentives for research and development of new drugs by the pharmaceutical industry

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          En el trabajo se desarrolló un modelo con los factores que influyen sobre la decisión de I+D de la industria farmacéutica. Los factores son el riesgo de contagio y la posibilidad de controlarlo; la letalidad y la presencia de curas o tratamientos; el ingreso; el número de personas que demandan y los costos de oportunidad de la empresa. Las empresas invertirán en mercados con demandas más inelásticas (enfermedades muy contagiosas sin posibilidad de controlar la transmisión y/o muy letales sin curas o tratamientos) y/o donde los demandantes tienen elevados ingresos y/o son numerosos. No invertirá en mercados donde sus costos marginales son superiores a sus ingresos marginales, particularmente cuando sus costos incrementan permanentemente como consecuencia del aumento del costo de oportunidad generado por lo que dejaría de ganar en otros mercados. Para estos casos, las políticas de subsidio de la I+D no son efectivas, por lo tanto, éstas deben orientarse al fortalecimiento de las investigaciones, tanto básica como aplicada, realizadas por las instituciones públicas o sin fines de lucro.

          Translated abstract

          The authors present a model with factors that influence research and development decisions by the pharmaceutical industry: risk of disease transmission and possibility of control; case-fatality and the presence of cure or treatments; income; number of persons who demand the medicine; and opportunity costs for the company. Companies tend to invest in markets with inelastic demand (highly contagious diseases with no possibility of controlling transmission and/or very lethal diseases without treatment) and/or where there is a large population or high per capita income. Companies tend not to invest in markets where marginal costs exceed marginal income, particularly when costs increase permanently as a consequence of rising opportunity costs generated by foregoing profit in other markets. In such cases, policies to subsidize R&D are not effective, and policies must be orientated towards strengthening basic and applied research by public institutions.

          Related collections

          Most cited references3

          • Record: found
          • Abstract: not found
          • Article: not found

          Desequilibrio fatal: a crise em pesquisa e desenvolvimento de drogas para doenças negligenciadas

          (2001)
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Avian influenza: frequently asked questions

            (2005)
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Desequilíbrio fatal: a crise em pesquisa e desenvolvimento de drogas para doenças negligenciadas

              (1999)
                Bookmark

                Author and article information

                Journal
                csp
                Cadernos de Saúde Pública
                Cad. Saúde Pública
                Escola Nacional de Saúde Pública Sergio Arouca, Fundação Oswaldo Cruz (Rio de Janeiro, RJ, Brazil )
                0102-311X
                1678-4464
                October 2008
                : 24
                : 10
                : 2363-2375
                Affiliations
                [01] Caracas orgnameUniversidad Simón Bolívar orgdiv1Departamento de Ciencias Económicas y Administrativas Venezuela
                Article
                S0102-311X2008001000017 S0102-311X(08)02401017
                10.1590/S0102-311X2008001000017
                c7069c12-c9bf-4cc2-8574-cf97cb6daef3

                This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

                History
                : 06 March 2008
                : 30 April 2007
                : 11 December 2008
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 7, Pages: 13
                Product

                SciELO Public Health

                Self URI: Texto completo solamente en formato PDF (ES)

                Health Policies,Políticas de Salud,Motivation,Industria Farmacéutica,Preparaciones Farmacéuticas,Motivación,Pharmaceutical Industry,Pharmaceutical Preparations

                Comments

                Comment on this article